{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:49:09Z","timestamp":1776185349695,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jcin.2012.10.005","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T03:46:01Z","timestamp":1355802361000},"page":"1195-1208","source":"Crossref","is-referenced-by-count":15,"title":["Drug\u2013Drug Interactions in Cardiovascular Catheterizations and Interventions"],"prefix":"10.1016","volume":"5","author":[{"given":"Steven P.","family":"Dunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"David R.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Moliterno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2012.10.005_bib1","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1001\/jama.2008.892","article-title":"Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States","volume":"300","author":"Qato","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2012.10.005_bib2","first-page":"753","article-title":"Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data","volume":"10","author":"Solberg","year":"2004","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jcin.2012.10.005_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00002018-200225060-00012","article-title":"Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria","volume":"25","author":"Shakir","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.jcin.2012.10.005_bib4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jcin.2012.10.005_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCINTERVENTIONS.111.965186","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary","volume":"4","author":"Faxon","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2012.10.005_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2008.01.018","article-title":"Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention","volume":"101","author":"Aggarwal","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/eurheartj\/ehn126","article-title":"Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative","volume":"29","author":"Wang","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2012.10.005_bib8","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.jacc.2012.02.010","article-title":"American College of Cardiology Foundation\/Society for Cardiovascular Angiography and Interventions expert consensus document on cardiac catheterization laboratory standards update","volume":"59","author":"Bashore","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2012.10.005_bib10","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2012.10.005_bib11","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.jacc.2006.05.058","article-title":"A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes","volume":"48","author":"Cohen","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ahj.2009.05.022","article-title":"Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin, (STACKENOX) study","volume":"158","author":"Drouet","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2012.10.005_bib13","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jacc.2007.12.052","volume":"51","author":"White","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib14","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2012.10.005_bib15","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.jacc.2011.02.011","volume":"57","author":"Wright","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2012.10.005_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1540-8183.2005.04065.x","article-title":"Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction","volume":"18","author":"Mattichak","year":"2005","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib18","first-page":"162","article-title":"Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding","volume":"18","author":"Khurram","year":"2006","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jcin.2007.11.004","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation","volume":"1","author":"Rogacka","year":"2008","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.10.005_bib20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/eurheartj\/ehm186","article-title":"Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?","volume":"28","author":"Nguyen","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2012.10.005_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2009.03.044","article-title":"Combining antiplatelet and anticoagulant therapies","volume":"54","author":"Holmes","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2012.10.005_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clpt.2006.05.004","article-title":"Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease","volume":"80","author":"Renda","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2012.10.005_bib24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2012.10.005_bib25","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","article-title":"Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association","volume":"115","author":"Antman","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.10.005_bib27","article-title":"Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study","author":"Meek","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jcin.2012.10.005_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1476-5381.2009.00243.x","article-title":"The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers","volume":"157","author":"Schuijt","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jcin.2012.10.005_bib29","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjcard.2007.11.054","article-title":"The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers","volume":"101","author":"Gladding","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/bmc.1128","article-title":"Clopidogrel: review of bioanalytical methods, pharmacokinetics\/pharmacodynamics, and update on recent trends in drug-drug interaction studies","volume":"23","author":"Mullangi","year":"2009","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.jcin.2012.10.005_bib31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/dmd.105.007989","article-title":"Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450","volume":"34","author":"Rehmel","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jcin.2012.10.005_bib32","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"52","author":"Bhatt","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib33","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","article-title":"Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel","volume":"101","author":"Sibbing","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2012.10.005_bib34","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.ahj.2008.09.017","article-title":"Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel","volume":"157","author":"Siller-Matula","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2012.10.005_bib35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2012.10.005_bib36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2012.10.005_bib38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.jcin.2012.10.005_bib39","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1592\/phco.30.8.787","article-title":"Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study","volume":"30","author":"Kreutz","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcin.2012.10.005_bib40","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCULATIONAHA.110.965640","volume":"123","author":"Simon","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.10.005_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-152-6-201003160-00003","article-title":"Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study","volume":"152","author":"Ray","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcin.2012.10.005_bib42","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2012.10.005_bib43","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jacc.2010.09.010","volume":"56","author":"Abraham","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib45","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1086-5802(16)31104-4","article-title":"HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles","volume":"40","author":"Beaird","year":"2000","journal-title":"J Am Pharm Assoc (Wash)"},{"key":"10.1016\/j.jcin.2012.10.005_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.10.005_bib47","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/01.CIR.0000124581.18191.15","article-title":"Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes","volume":"109","author":"Mitsios","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.10.005_bib48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.amjcard.2006.08.036","article-title":"Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis","volume":"99","author":"Wenaweser","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib49","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehn212","article-title":"Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy","volume":"29","author":"Geisler","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2012.10.005_bib50","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1161\/01.CIR.0000099507.32936.C0","article-title":"Effects of statins on platelet inhibition by a high loading dose of clopidogrel","volume":"108","author":"M\u00fcller","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.10.005_bib51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0021-9150(01)00606-2","article-title":"Statins do not affect platelet inhibition with clopidogrel during coronary stenting","volume":"159","author":"Serebruany","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcin.2012.10.005_bib52","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000088780.57432.43","article-title":"Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial","volume":"108","author":"Saw","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.10.005_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2007.01.097","article-title":"Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial","volume":"50","author":"Saw","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib54","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.ahj.2007.12.009","volume":"155","author":"Lotfi","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2012.10.005_bib55","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","author":"Siller-Matula","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/hrt.2009.171488","article-title":"Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition","volume":"96","author":"Gremmel","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.jcin.2012.10.005_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1161\/CIRCINTERVENTIONS.111.963405","article-title":"Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial","volume":"5","author":"Good","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2012.10.005_bib58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.toxlet.2011.01.027","article-title":"Drug-drug interactions by azole antifungals: beyond a dogma of CYP3A4 enzyme activity inhibition","volume":"202","author":"Dvorak","year":"2011","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.jcin.2012.10.005_bib59","first-page":"14","article-title":"The clinical pharmacology of fluconazole","volume":"17","author":"Lazar","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jcin.2012.10.005_bib60","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.clpt.6100139","article-title":"Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently","volume":"81","author":"Farid","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2012.10.005_bib61","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/eurheartj\/ehq023","article-title":"Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel","volume":"31","author":"Sibbing","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2012.10.005_bib62","series-title":"Brilinta","year":"2011"},{"key":"10.1016\/j.jcin.2012.10.005_bib63","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.10.005_bib64","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000324064","article-title":"Aspirin dose and ticagrelor benefit in PLATO: fact or fiction?","volume":"117","author":"Serebruany","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.jcin.2012.10.005_bib65","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/00000542-200204000-00031","article-title":"Practice guidelines for sedation and analgesia by non-anesthesiologists","volume":"96","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jcin.2012.10.005_bib66","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/00000542-199011000-00005","article-title":"Frequent hypoxemia and apnea after sedation with midazolam and fentanyl","volume":"73","author":"Bailey","year":"1990","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jcin.2012.10.005_bib67","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2710.1999.00247.x","article-title":"Clinically significant pharmacokinetic drug interactions with benzodiazepines","volume":"24","author":"Tanaka","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jcin.2012.10.005_bib68","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1365-2044.2003.03339.x","article-title":"The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam","volume":"58","author":"McDonnell","year":"2003","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jcin.2012.10.005_bib69","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1994.tb04266.x","article-title":"Dose of midazolam should be reduced during diltiazem and verapamil treatments","volume":"37","author":"Backman","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jcin.2012.10.005_bib70","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/00000542-199612000-00004","article-title":"Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting","volume":"85","author":"Ahonen","year":"1996","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jcin.2012.10.005_bib71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.psy.50.2.169","article-title":"Pharmacokinetic drug interactions of synthetic opiate analgesics","volume":"50","author":"Armstrong","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jcin.2012.10.005_bib72","doi-asserted-by":"crossref","first-page":"648.e9","DOI":"10.1016\/j.genhosppsych.2010.08.003","article-title":"Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction","volume":"32","author":"Levin","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jcin.2012.10.005_bib73","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Shitara","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jcin.2012.10.005_bib74","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","article-title":"Plasma concentrations of active simvastatin acid are increased by gemfibrozil","volume":"68","author":"Backman","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2012.10.005_bib75","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0091270010366446","article-title":"Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin","volume":"51","author":"Whitfield","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jcin.2012.10.005_bib76","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2012.10.005_bib77","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2796.1996.48879000.x","article-title":"Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil","volume":"240","author":"van Puijenbroek","year":"1996","journal-title":"J Intern Med"},{"key":"10.1016\/j.jcin.2012.10.005_bib78","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/00007611-199705000-00018","article-title":"Rhabdomyolysis associated with simvastatin-gemfibrozil therapy","volume":"90","author":"Tal","year":"1997","journal-title":"South Med J"},{"key":"10.1016\/j.jcin.2012.10.005_bib79","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9149(97)00907-7","article-title":"Rhabdomyolysis after taking atorvastatin with gemfibrozil","volume":"81","author":"Duell","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.977","article-title":"Rhabdomyolysis with HMG-CoA Reductase inhibitors and gemfibrozil combination therapy","volume":"13","author":"Chang","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jcin.2012.10.005_bib81","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jclinepi.2006.11.006","article-title":"Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population","volume":"60","author":"McClure","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jcin.2012.10.005_bib82","series-title":"Crestor [package insert]","year":"2010"},{"key":"10.1016\/j.jcin.2012.10.005_bib83","series-title":"Mevacor [package insert]","year":"2010"},{"key":"10.1016\/j.jcin.2012.10.005_bib85","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1067\/mcp.2000.104609","article-title":"The interaction of diltiazem with simvastatin","volume":"67","author":"Mousa","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2012.10.005_bib86","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0009-9236(98)90067-4","article-title":"The interaction of diltiazem with lovastatin and pravastatin","volume":"64","author":"Azie","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2012.10.005_bib87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000046056","article-title":"Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem","volume":"89","author":"Peces","year":"2001","journal-title":"Nephron"},{"key":"10.1016\/j.jcin.2012.10.005_bib88","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1345\/aph.1A481","article-title":"Rhabdomyolysis with concurrent atorvastatin and diltiazem","volume":"36","author":"Lewin","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jcin.2012.10.005_bib89","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1291\/hypres.28.223","article-title":"Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension","volume":"28","author":"Nishio","year":"2005","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jcin.2012.10.005_bib90","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5414\/CPP48497","article-title":"Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin","volume":"48","author":"Park","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2012.10.005_bib91","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879812009934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879812009934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T04:38:26Z","timestamp":1562474306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879812009934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":88,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1936879812009934"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2012.10.005","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}